1. From 2016-2020, the 14 biggest drug makers spent $56 BILLION more on stock buybacks and dividends than R&D.

$56B more to enrich execs & investors instead of developing & improving medications.

They're projected to spend $1.15 trillion on buybacks & dividends from 2020-2029. pic.twitter.com/OWXGhUdEs5

— Carolyn B. Maloney (@RepMaloney) July 8, 2021